NASDAQ:IOBT IO Biotech (IOBT) Stock Price, News & Analysis → Tiny, One-Half Inch Pellet the Key to INFINITE Energy? (From Eagle Publishing) (Ad) Free IOBT Stock Alerts $1.31 +0.03 (+2.34%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$1.30▼$1.3250-Day Range$1.18▼$1.6052-Week Range$0.82▼$2.20Volume180,148 shsAverage Volume124,036 shsMarket Capitalization$86.30 millionP/E RatioN/ADividend YieldN/APrice Target$9.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get IO Biotech alerts: Email Address IO Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside643.6% Upside$9.67 Price TargetShort InterestHealthy0.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 3 Articles This WeekInsider TradingSelling Shares$803,747 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.27) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.34 out of 5 starsMedical Sector526th out of 917 stocksPharmaceutical Preparations Industry245th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingIO Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIO Biotech has only been the subject of 1 research reports in the past 90 days.Read more about IO Biotech's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.21% of the float of IO Biotech has been sold short.Short Interest Ratio / Days to CoverIO Biotech has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IO Biotech has recently increased by 129.35%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIO Biotech does not currently pay a dividend.Dividend GrowthIO Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IOBT. Previous Next 3.3 News and Social Media Coverage News SentimentIO Biotech has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for IO Biotech this week, compared to 1 article on an average week.Search Interest3 people have searched for IOBT on MarketBeat in the last 30 days. MarketBeat Follows2 people have added IO Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IO Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $803,747.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of IO Biotech is held by insiders.Percentage Held by Institutions54.76% of the stock of IO Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IO Biotech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IO Biotech are expected to decrease in the coming year, from ($1.27) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IO Biotech is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IO Biotech is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIO Biotech has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about IO Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having to buy a single stock?Click here now to claim your FREE copy of Marc's AI playbook. About IO Biotech Stock (NASDAQ:IOBT)IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Read More IOBT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOBT Stock News HeadlinesMay 15, 2024 | insidertrades.comInsider Selling: IO Biotech, Inc. (NASDAQ:IOBT) Major Shareholder Sells 658,809 Shares of StockMay 27, 2024 | finance.yahoo.comWill IO Biotech (NASDAQ:IOBT) Spend Its Cash Wisely?May 23, 2024 | globenewswire.comIO Biotech to Present at Jefferies Global Healthcare ConferenceMay 15, 2024 | markets.businessinsider.comOptimistic Buy Rating for IO Biotech Amidst Promising Clinical Trial Progress and Accelerated PFS Data TimelineMay 14, 2024 | investorplace.comIOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024May 14, 2024 | globenewswire.comIO Biotech Reports First Quarter 2024 Financial Results and Provides Business HighlightsApril 24, 2024 | globenewswire.comIO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 17, 2024 | msn.comIO Biotech (IOBT) Price Target Decreased by 11.11% to 8.16April 15, 2024 | globenewswire.comIO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessApril 11, 2024 | investing.comIO Biotech presents cancer vaccine data at AACRApril 9, 2024 | globenewswire.comIO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103April 5, 2024 | globenewswire.comIO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerMarch 7, 2024 | finance.yahoo.comIO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical TrialsMarch 6, 2024 | markets.businessinsider.comBuy Recommendation for IO Biotech on Strong Data Prospects and Undervalued Stock PositionMarch 6, 2024 | morningstar.comIO Biotech Inc IOBTMarch 6, 2024 | msn.comIO Biotech GAAP EPS of -$0.40 misses by $0.02March 6, 2024 | globenewswire.comIO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 5, 2024 | investorplace.comIOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023March 5, 2024 | globenewswire.comIO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsFebruary 26, 2024 | globenewswire.comIO Biotech to Present at 44th Annual Cowen Health Care ConferenceFebruary 4, 2024 | msn.comWhat's Next for Iovance Biotherapeutics Stock?January 15, 2024 | finance.yahoo.comIO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%January 3, 2024 | seekingalpha.comIO Biotech: A Phase 3 Company Getting No RespectDecember 21, 2023 | finance.yahoo.comIO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialDecember 19, 2023 | finance.yahoo.comWe're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn RateSee More Headlines Receive IOBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/14/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IOBT CUSIPN/A CIK1865494 Webwww.iobiotech.com Phone45-7070-2980FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$9.67 High Stock Price Target$12.00 Low Stock Price Target$7.00 Potential Upside/Downside+637.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.31% Return on Assets-62.21% Debt Debt-to-Equity RatioN/A Current Ratio11.24 Quick Ratio11.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.02 per share Price / Book0.65Miscellaneous Outstanding Shares65,880,000Free Float64,366,000Market Cap$86.30 million OptionableNot Optionable Beta0.46 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Mai-Britt Zocca Ph.D. (Age 56)Founder, President, CEO, Principal Financial Officer & Director Comp: $892.24kMr. Devin Whittemore Smith (Age 56)Secretary, General Counsel & Chief Compliance Officer Comp: $621.8kDr. Qasim Iftikhar Ahmad M.D. (Age 53)Chief Medical Officer Comp: $503.28kProf. Inge Marie Svane M.D.Ph.D., Founder & Clinical AdvisorProf. Mads Hald Andersen M.D.Ph.D., Founder & Scientific AdvisorAnders LjungqvistFounderProf. Per Thor StratenFounderMs. Amy B. Sullivan M.B.A. (Age 53)Chief Financial Officer Comp: $391.24kMr. Eric Faulkner M.B.A.Chief Technical OfficerMr. Daniel G. Mannix Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsDURECTNASDAQ:DRRXaTyr PharmaNASDAQ:LIFEXeris BiopharmaNASDAQ:XERSEmergent BioSolutionsNYSE:EBSAtea PharmaceuticalsNASDAQ:AVIRView All CompetitorsInsidersHoldings A/S NovoSold 658,809 sharesTotal: $803,746.98 ($1.22/share)Holdings A/S NovoSold 658,809 sharesTotal: $988,213.50 ($1.50/share)Brian BurkavageBought 5,000 shares on 11/21/2023Total: $4,950.00 ($0.99/share)Vivo Capital Ix, LlcBought 3,157,894 shares on 8/9/2023Total: $6.00 M ($1.90/share)View All Insider Transactions IOBT Stock Analysis - Frequently Asked Questions Should I buy or sell IO Biotech stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IOBT shares. View IOBT analyst ratings or view top-rated stocks. What is IO Biotech's stock price target for 2024? 3 Wall Street analysts have issued 1-year price objectives for IO Biotech's stock. Their IOBT share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.67 in the next twelve months. This suggests a possible upside of 643.6% from the stock's current price. View analysts price targets for IOBT or view top-rated stocks among Wall Street analysts. How have IOBT shares performed in 2024? IO Biotech's stock was trading at $1.88 on January 1st, 2024. Since then, IOBT shares have decreased by 30.9% and is now trading at $1.30. View the best growth stocks for 2024 here. Are investors shorting IO Biotech? IO Biotech saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 92,200 shares, an increase of 129.4% from the May 15th total of 40,200 shares. Based on an average daily trading volume, of 98,200 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.2% of the company's shares are sold short. View IO Biotech's Short Interest. When is IO Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our IOBT earnings forecast. How were IO Biotech's earnings last quarter? IO Biotech, Inc. (NASDAQ:IOBT) issued its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.07. When did IO Biotech IPO? IO Biotech (IOBT) raised $111 million in an IPO on Friday, November 5th 2021. The company issued 7,150,000 shares at a price of $14.00-$17.00 per share. How do I buy shares of IO Biotech? Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IOBT) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. ...The Freeport Society | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.